Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 70 versus VISIPAQUE 320.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 70 versus VISIPAQUE 320.
OMNIPAQUE 70 vs VISIPAQUE 320
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast by increasing the density of blood vessels and organs.
Iodinated nonionic radiocontrast agent that attenuates X-rays and enhances vascular and tissue contrast.
1.5-2.0 mL/kg IV for contrast enhanced CT, max 150 mL; intra-arterial: 5-40 mL per injection depending on procedure.
Intravascular administration: Adult dose is 50-150 mL (16-48 g iodine) intravenously as a bolus or infusion, depending on the procedure. For CT imaging, typical dose is 75-150 mL at 1-3 mL/sec.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe dysfunction).
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. Clinically, clearance is prolonged in renal impairment, requiring dose adjustment.
Renal: 100% unchanged via glomerular filtration. No biliary or fecal elimination.
Primarily renal via glomerular filtration; approximately 95% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent